Grade My Investments

10x Genomics, Inc. (TXG) Stock Grade

TXG · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$2.0B
P/E Ratio
Revenue Growth (YoY)
+5.3%
Net Margin
-6.8%
Return on Equity
Dividend Yield
None

About 10x Genomics, Inc.'s fundamentals

10x Genomics is a healthcare information services company with a $2.0 billion market cap that generated 5.3% year-over-year revenue growth in its latest period. The company is currently unprofitable, with a net margin of -6.8%, and reported a net loss in its latest annual statement. Despite the accounting losses, 10x Genomics maintains positive free cash flow, indicating the business is generating cash from operations even as it operates at a net loss.

Track TXG free — no credit card required. Live grade + monthly AI report →